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Abstract 
We evaluated the detection of pseudorabies virus (PRV) antibodies in swine oral fluid. Oral fluid and 
serum samples were obtained from 40 pigs allocated to 4 treatment groups (10 pigs/group): negative 
control (NC); wild-type PRV inoculation (PRV 3CR Ossabaw; hereafter PRV); PRV vaccination (Ingelvac 
Aujeszky MLV; Boehringer Ingelheim; hereafter MLV); and PRV vaccination followed by PRV inoculation at 
21 d post-vaccination (MLV-PRV). Using a serum PRV whole-virus indirect IgG ELISA (Idexx Laboratories) 
adapted to the oral fluid matrix, PRV antibody was detected in oral fluid samples from treatment groups 
PRV, MLV, and MLV-PRV in a pattern similar to serum. Vaccination alone produced a low oral fluid 
antibody response (groups MLV and MLV-PRV), but a strong anamnestic response was observed 
following challenge with wild-type virus (group PRV). Analyses of the oral fluid PRV indirect IgG ELISA 
results showed good binary diagnostic performance (area under ROC curve = 93%) and excellent assay 
repeatability (intra-class correlation coefficient = 99.3%). The demonstrable presence of PRV antibodies in 
swine oral fluids suggests the possible use of oral fluids in pseudorabies surveillance. 
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Pseudorabies virus (PRV; Suid alphaherpesvirus 1) is an 
enveloped DNA virus in family Herpesviridae, subfamily 
Alphaherpesvirinae. Swine are the natural host of PRV.30 In 
domestic pigs (Sus scrofa domesticus), the clinical expres-
sion of PRV infection ranges from inapparent to nearly 100% 
mortality in susceptible piglets.35,37,43 Typical of herpesvi-
ruses, PRV establishes latency in pigs that survive acute 
infection, with virus subsequently detectable in trigeminal 
ganglion, olfactory bulb, and tonsil tissues.13,31,34,36
Beginning in the 1960s, clinical PRV became increas-
ingly problematic in commercial swine herds in Europe, the 
Americas, and Southeast Asia, with annual losses estimated 
at US$21 to $25 million to U.S. producers.21,25 The develop-
ment of efficacious PRV marker vaccines and differential 
serum antibody ELISA made PRV eradication possible from 
domestic swine (e.g., Great Britain in 1991, Germany in 2003, 
New Zealand in 1997, the United States in 2004),3,14,23,27,42 
but PRV continues to present a risk to commercial swine pro-
ducers because it remains endemic in feral swine populations 
in Europe,22,39,40 Asia,16,19 and the Western Hemisphere.24,26,29 
In the United States, PRV has occasionally been introduced 
into “transitional” herds via contact with feral swine (e.g., 
Minnesota in 2002, Wisconsin in 2007). In France, PRV 
was detected in 2019 in 2 farms reportedly via contact with 
feral swine.11 Under these circumstances, improvements in 
PRV testing, surveillance, control, and elimination remain 
relevant.
The purpose of disease surveillance is to monitor herd 
immunity and/or to determine population infection status. 
In the case of pathogens for which marker vaccines and 
corresponding assays have been developed, both functions 
can be achieved simultaneously. PRV control and eradica-
tion has been achieved in many parts of the world using 
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Abstract. We evaluated the detection of pseudorabies virus (PRV) antibodies in swine oral fluid. Oral fluid and serum 
samples were obtained from 40 pigs allocated to 4 treatment groups (10 pigs/group): negative control (NC); wild-type 
PRV inoculation (PRV 3CR Ossabaw; hereafter PRV); PRV vaccination (Ingelvac Aujeszky MLV; Boehringer Ingelheim; 
hereafter MLV); and PRV vaccination followed by PRV inoculation at 21 d post-vaccination (MLV-PRV). Using a serum 
PRV whole-virus indirect IgG ELISA (Idexx Laboratories) adapted to the oral fluid matrix, PRV antibody was detected in oral 
fluid samples from treatment groups PRV, MLV, and MLV-PRV in a pattern similar to serum. Vaccination alone produced 
a low oral fluid antibody response (groups MLV and MLV-PRV), but a strong anamnestic response was observed following 
challenge with wild-type virus (group PRV). Analyses of the oral fluid PRV indirect IgG ELISA results showed good binary 
diagnostic performance (area under ROC curve = 93%) and excellent assay repeatability (intra-class correlation coefficient 
= 99.3%). The demonstrable presence of PRV antibodies in swine oral fluids suggests the possible use of oral fluids in 
pseudorabies surveillance.
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glycoprotein E (gE)-deleted PRV MLVs and gB/gE serum 
ELISAs.2,10,12,41,44
Current PRV differentiation of infected and vaccinated 
animals (DIVA) serum ELISAs are designed for testing indi-
vidual pigs, whereas the industry is moving toward the use of 
population-based specimens (e.g., processing fluid samples 
and group-level oral fluid samples) as a means to achieve a 
higher probability of detection at a lower cost.4 Commercial 
serum ELISAs can often be adapted to the oral fluid matrix 
by accounting for the lower concentration of IgG antibody in 
oral fluid.6,24 In general, this involves adjusting 4 variables: 
1) sample volume and/or dilution ratio, 2) incubation time, 3) 
incubation temperature, and 4) conjugates and/or substrates. 
Including both nucleic acid and antibody testing, the veteri-
nary diagnostic laboratories at Iowa State University, South 
Dakota State University, and the University of Minnesota 
performed > 350,000 tests on swine oral fluid specimens in 
2016.4 These developments were driven by the ease of oral 
fluid sampling in the field and the emergence of sensitive and 
specific assays adapted to the oral fluid matrix. Continuing 
this line of research, we explored the detection of PRV anti-




We evaluated the detection of PRV antibody in swine serum 
(n = 350) and oral fluid (n = 1,540) samples of known infec-
tion and/or vaccination status using an indirect serum PRV 
IgG ELISA (Idexx Laboratories). Samples were obtained 
from 12- to 16-wk-old pigs in 4 treatment groups (10 pigs/
group): negative control (NC), wild-type PRV inoculated 
(PRV), PRV vaccinated (MLV), and PRV vaccinated and 
challenged at 3 wk post-vaccination (MLV-PRV). Depending 
on the group, serum and oral fluid samples were collected 
from individual animals for up to 49 d (Table 1). Serum sam-
ples were tested as prescribed by the manufacturer, whereas 
oral fluid samples were tested using a modified protocol. 
Receiver operating characteristic (ROC) curve analysis was 
used to evaluate test performance. The repeatability of serum 
and oral fluid ELISAs was calculated for both quantitative 
and qualitative results. All procedures were approved by the 
U.S. Department of Agriculture–Agricultural Research Ser-
vice and Iowa State University Institutional Animal Care and 
Use Committees.
Virus inoculum
Animals were inoculated with wild-type PRV (PRV isolate 
3CR Ossabaw) propagated on swine testicular (ST) cells.47 
In brief, a monolayer of ST cells in a 75-cm2 flask was 
inoculated with virus (0.5 mL, 1 × 106.8 TCID
50
/mL). When 
cytopathic effect (CPE) was observed in 80–90% of the 
monolayer, the flask was subjected to 2 freeze–thaw cycles 
(–80°C), the harvested contents were clarified by centrifuga-
tion (1,000 × g for 10 min), and the supernatant stored in 
0.5-mL aliquots at –80°C.47
Virus titrations were done on confluent monolayers of ST 
cells in 96-well plates. Virus solutions were serially 10-fold 
diluted (10-1–10-9) in minimum essential medium (Milli-
poreSigma) and then columns of wells preloaded with main-
tenance medium (100 µL) were inoculated with each dilution 
(100 µL). Plates were incubated at 37°C in a humidified 5% 
CO
2
 incubator and then examined for CPE at 72 h. Virus 
titers and 95% CIs were calculated using the Spearman–
Kärber method (http://www.klinikum.uni-heidelberg.de/
Downloads.126386.0.html).17,38
Animals and treatment groups
Forty 12- to 16-wk-old crossbred domestic pigs were 
obtained from a commercial swine herd in the north-central 
United States. All pigs were confirmed negative for porcine 
reproductive and respiratory syndrome virus antibodies 
before the start of the experiment. Pigs were individually 
housed in pens (1.5 × 1.5 m) constructed of gates allowing 
interaction between animals in neighboring pens. Each pen 
was equipped with a nipple drinker and a bracket from which 
to suspend a rope for oral fluid collection.
Limitations in facility space dictated that pigs were 
received in 2 lots (10 and 30 pigs) and likewise determined 
the length of observation for each group. Groups MLV, PRV, 
and MLV-PRV were housed for 27, 38, and 62 d, respec-
tively, in a biosafety level 3 (BSL3-Ag) high-containment 
animal facility at the USDA–National Animal Disease Cen-
ter (Ames, IA). Group NC was held for 54 d in a BSL-2 
livestock infectious disease isolation facility at Iowa State 
University (Ames, IA; Table 1). On day 0, pigs were ran-
domly assigned to treatment groups by blindly selecting ear 
tags from a bag and then housed individually in pens. On day 
7, pigs in the MLV and MLV-PRV groups were vaccinated 
intramuscularly with a 2-mL dose of a commercial vaccine 
(Ingelvac Aujeszky MLV; Boehringer Ingelheim). On day 
28, pigs in the PRV and MLV-PRV groups were intranasally 
exposed to 2 mL of an inoculum containing 1 × 102.9 TCID
50
/mL 
(95% CI: 1 × 102.5 and 1 × 103.3) PRV isolate 3CR Ossabaw 
into each naris (i.e., 1 × 103.5 TCID
50
 per pig; Table 1).
Throughout the experiment, pigs were observed at least 
twice daily for general health and signs of infectious disease. 
All animals were managed identically and, at the termination 
of the study, all animals were euthanized by captive bolt or 
chemical injection followed by exsanguination, as specified 
in the American Veterinary Medical Association Guidelines 
for the Euthanasia of Animals.1
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Biological specimens
Blood samples (Table 1) were collected from the external 
jugular vein using 20-ga needles (Exelint International), 
reusable hubs (Becton Dickinson), and 12.5-mL serum sepa-
rator tubes (Covidien). Serum was harvested by centrifuga-
tion (1,000 × g for 15 min), aliquoted into 2-mL cryogenic 
vials (Cryovial; Greiner Bio-One), and stored at –20°C.
Oral fluid samples (Table 1) were collected from individ-
ual pigs daily by hanging 1.27 cm (0.5 in) diameter, 
3-stranded, 100% cotton rope (Web Rigging Supply) from 
metal brackets installed in each pen.15,46 Rope length and 
bracket height were adjusted to the size of pigs and placed to 
avoid contact with the floor. After allowing pigs to interact 
with the ropes for 30–45 min, the wet portion of the rope was 
placed in a plastic bag (Elkway Plastics) and passed through 
a chamois wringer (Dyna-Jet Products). Liquid that pooled 
in the bag was decanted into 50-mL conical centrifuge tubes 
(Falcon; Fisher Scientific) and stored at –20°C.
PRV indirect IgG ELISA
Serum and oral fluid samples were tested for PRV IgG using a 
PRV indirect serum ELISA based on the Shope strain of PRV 
(Idexx ADV(S) indirect ELISA; Idexx Laboratories). Serum 
samples were tested and the results interpreted according to 
the manufacturer’s instructions. Negative (3 wells), weak-
positive (3 wells), and strong-positive (2 wells) controls for 
plate validation and calculating results were provided by the 
manufacturer. Results were standardized as sample-to-positive 
(S/P) ratios (equation 1), and samples with S/P ratios ≥0.4 were 
classified as PRV antibody positive (OD = optical density).
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Oral fluid samples were tested by the PRV indirect IgG 
serum ELISA using a modified protocol. Samples (100 µL) 
were first diluted (1:1) with kit diluent, then 100 µL was 
added to each well and the plates incubated for 16 ± 2 h at 
4°C. Wells were washed 5 times with kit wash solution 
(300 µL), then goat anti-pig IgG (Bethyl Laboratories) 
diluted 1:2,000 was added to each well (100 µL), and the 
plates incubated at 37°C for 2 h. The remainder of the proce-
dure was performed as per the manufacturer’s instructions. 
Negative and positive controls for plate validation and S/P 
calculation consisted of oral fluid samples derived from the 
animal inoculation study with oral fluid OD values of 0.09 ± 
0.01 and 1.02 ± 0.06, respectively. Oral fluid S/P ratios were 
calculated as shown in equation 2.
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ELISA repeatability. The repeatability of the PRV serum 
and oral fluid ELISAs was quantified by calculating intra-
class correlation coefficients (ICC) using the R package irr 
(v.0.84.1) and the results interpreted based on established 
guidelines (https://cran.r-project.org/web/packages/irr/index.
html).18 Among the methods described for quantifying repeat-
ability, ICC was chosen because it is better suited to manage 
> 2 test repeats.5 The repeatability analysis was based on 
ELISA testing of a subset of 40 oral fluid and 40 serum sam-
ples randomly selected from each of the 10 animals in each 
of the 4 treatment groups. A sample size of 40 was calculated 
using equation 3, in which n is the number of samples, m is 
the number of repetitions for each sample, and Z
1-(α/2)
 indi-
cates the 100(1-α/2)th percentile of the standard normal dis-
tribution.20 Solving equation 3 for n produced equation 4. 
The 2-tailed α was set at 0.05, therefore, the half-width of the 
95% CI of the within-subject standard deviation (S
w
) estima-
tion was set at 10%. Variation between plates and kit lots 
was assumed to be equal across all tests (i.e., measurement 
variation was the variable of interest).






Vaccination* Inoculation† Serum (d) Oral fluid (d)
NC 10 NA NA 0, 7, 11, 14, 17, 21, 24, 28, 35, 42, 49 0–49 daily
PRV 10 NA Day 28 23, 28, 35, 42, 49 23–49 daily
MLV 10 Day 7 NA 2, 7, 11, 13, 16, 20, 23, 27 0–26 daily
MLV-PRV 10 Day 7 Day 28 2, 7, 11, 13, 16, 20, 23, 27, 34, 41, 48 0–49 daily
MLV = vaccination only; MLV-PRV = vaccination then pseudorabies virus inoculation; NA = not applicable; NC = negative control; PRV = PRV inoculation only.
* Intramuscular injection of PRV modified live virus (MLV) vaccine (Ingelvac Aujeszky MLV; Boehringer Ingelheim).
† Intranasal inoculation of PRV strain 3CR Ossabaw (1 × 103.5 TCID
50
 per pig).
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This subset of samples was tested 6 times using the previ-
ously described specimen-specific procedures, thereby pro-
ducing 240 S/P ratios for each of the 2 sample types. 
Thereafter, the ICC was estimated using a 3-step approach: 
1) a 2-way mixed-effects model was used to estimate intra-
replicate reliability and avoid the influence of heterogeneity, 
2) S/P ratios from the first replicate were used as a baseline, 
and 3) “absolute agreement” was used to determine whether 
different replicates assigned the same measurement to the 
same samples.18 Higher correlation suggested fewer mea-
surement errors and better repeatability.7 Previously estab-
lished ICC classification guidelines18 were used to interpret 
the repeatability of the indirect PRV IgG ELISA testing 
serum and oral fluid samples: 1) < 50% (poor); 2) 50–75% 
(moderate); 3) 75–90% (good); 4) > 90% (excellent).
Serum versus oral fluid ELISA responses. The relationship 
between serum and oral fluid testing was evaluated by fitting 
the data to a cubic linear regression model. Before fitting the 
model, S/P ratios from paired serum (n = 350) and oral fluid 
samples (n = 350; pig by day of study) were transformed 
(log
10
) to normalize the model residuals. In addition, the 
average ranked ELISA S/P ratios from serum and oral fluid 
samples were compared using a nonparametric test (Kruskal–
Wallis) because the assumption of normality was rejected 
(Shapiro–Wilk test, p < 0.001) for both the raw and trans-
formed (square root, cube root, and log) ELISA results from 
serum (n = 350) and oral fluid (n = 350) samples paired by 
day of study.
ROC analysis. ROC curve analyses were done to evaluate 
the performance of the serum and oral fluid ELISAs using R 
software package pROC (v.1.16.2; https://cran.r-project.org/
web/packages/pROC/index.html).32 Diagnostic sensitivity 
and specificity were derived from the ROC analyses for spe-
cific assay cutoffs. Associated 95% CIs were estimated using 
a procedure for normally distributed correlated data.9 Before 
performing the analyses, the S/P data of serum and oral fluid 
were normalized by 4/7 and 1/3 power transformations, 
respectively. ROC analyses require designation of the status 
(positive or negative) of the sample. Based on prior 
reports,28,45 sample status was defined as: 1) serum and oral 
fluid samples collected ≤ 7 d post-vaccination (dpv) or day 
post-inoculation (dpi) were classified as PRV antibody nega-
tive; 2) serum samples collected ≥ 10 dpv/dpi were consid-
ered antibody positive; 3) oral fluid samples collected ≥ 14 
dpv/dpi were considered antibody positive. The nonparamet-
ric DeLong method8 was used to estimate the 95% CIs for 
the area under the curve (AUC) and to compare serum and 
oral fluid AUCs. Typical methods for estimating CIs for pro-
portions are based on binomial distribution and do not 
account for the correlated structure of longitudinal data (i.e., 
repeated observations from the same animals over time). 
Therefore, a method for deriving CIs for correlated, normally 
distributed data was utilized.9 In brief, the correlation of the 
data was considered by fitting normalized data into a linear 
mixed model.
 Y sij i ij ij= + + +µ γ τ ε  (5)
In equation 5, Y
ij
 is the jth observation for the ith subject; 
µ is the overall mean for samples classified as PRV antibody 
negative; γ
i
 is the random effect of the ith subject; τ is the 
fixed effect indicating the mean difference between PRV 
antibody-negative and -positive groups; s
ij
 is the disease sta-
tus of the jth observation for the ith subject; and ε
ij
 is the 
random error of the jth observation for the ith subject. The 
variances from model 5 were used to calculate the 95% CIs 
for ROC-derived diagnostic sensitivity and diagnostic speci-
ficity estimates. Logit transformation was used to prevent the 




Animals in groups MLV-PRV, MLV, and NC remained clini-
cally healthy throughout the observation period. Clinical 
signs were observed in 3 of 10 animals in group PRV (i.e., 
lethargy, ataxia, and tremors beginning 7 dpi), but the clini-
cal signalment did not fulfill the IACUC-approved criteria 
for euthanasia and all animals were clinically normal by 14 
dpi. Individual oral fluid samples were successfully col-
lected (≥ 2 mL) from pigs in groups MLV-PRV, MLV, and 
NC in 1,182 of 1,230 attempts (96.1%). In group PRV, 246 
of 270 oral fluid collections (91.1%) were successful 
throughout the study. Coincident with the appearance of 
clinical signs, oral fluid samples were collected from 7 of 10 
pigs at 7 dpi, 8 of 10 pigs at 8–11 dpi, and either 9 or 10 pigs, 
thereafter.
PRV ELISA testing and performance
No PRV antibodies were detected in serum or oral fluid 
samples from negative control animals. In contrast, vac-
cination (group MLV) or inoculation (group PRV) pro-
duced detectable serum antibody responses by 10 dpv or 
14 dpi, and vaccination followed by inoculation (group 
MLV-PRV) produced a clear anamnestic response at 7 dpi 
PRV antibody in serum and oral fluid 5
(Fig. 1). Similar, but lower, antibody responses were 
observed in oral fluid specimens across all treatment groups 
(Kruskal–Wallis test, p < 0.001). The serum ELISA ICC 
was estimated at 99.0% (95% CI: 98.3, 99.5) and the oral 
fluid ELISA ICC was 99.3% (95% CI: 98.9, 99.6; i.e., both 
assays had excellent repeatability). The relationship between 
paired serum and oral fluid antibody S/P ratios was shown to 
fit the cubic curvilinear regression model shown in equa-
tion 6, in which oral fluid and serum stand for the trans-
formed (log
10
) S/P ratios (adjusted R2 = 0.6503, standard 
error = 0.4407).
 
oral fluid = 1.5658 + 1.5336 serum  
+ 1.1924 serum + 0
2
− ( )
( ) .2772 serum 3( )
 (6)
The AUCs, and hence the performance, for serum (n = 350) 
and oral fluid (n = 1,630) PRV ELISAs was different for 
the 2 curves (DeLong method, p < 0.001; Fig. 2). Likewise, 
estimated diagnostic sensitivities and specificities differed 
between the 2 assays (Table 2). For cases in which all test 
results were classified either as positive or negative at a 
specific cutoff (i.e., 100%), 95% CIs were estimated using 
sensitivity or specificity as 99.99% because logit(100%) is 
undefinable.
Discussion
The PRV indirect oral fluid IgG ELISA that we used pro-
vided “excellent” repeatability (ICC = 99.3%).18 Our adapted 
serum assay detected PRV antibody at ≥14 dpi in oral fluid 
specimens from virus-inoculated pigs and revealed a strong 
anamnestic response in vaccinated or challenged animals. In 
contrast, vaccine alone induced a low concentration of anti-
body in oral fluid (7–21 dpv).
PRV antibody has been detected in oropharyngeal swabs 
using a 4-layer enzyme immunoassay.33 We detected PRV 
IgG (10 dpv/dpi) in oropharyngeal swabs from vaccinated 
(n = 5) and inoculated (n = 7) pigs, whereas IgM (7 dpi) and 
IgA (10 dpi) were found only in inoculated pigs. Using pro-
cedures similar to those described herein, PRV antibodies 
were detected in oral fluids between 10 and 17 dpi following 
exposure to a wild-type PRV Thai isolate.47 Thus, our data 
agree with these earlier reports.28,33
Our results demonstrate the feasibility of detecting PRV 
antibodies in oral fluid specimens. This represents the first 
step toward the development of a DIVA-compatible oral 
fluid–based ELISA for use in PRV control and elimination 
programs.
Figure 1. Serum and oral fluid pseudorabies virus (PRV) 
antibody responses (x̅ ± standard error) based on ELISA testing 
(ADV (S) iELISA kit; Idexx Laboratories). Day 7: intramuscular 
administration of modified live virus vaccine (Ingelvac Aujeszky 
MLV; Boehringer Ingelheim). Day 28: intranasal administration of 
PRV isolate 3CR Ossabaw (1 × 103.5 TCID
50
 per pig). S/P = sample-
to-positive ratio.
Figure 2. Receiver operating characteristic (ROC) curve 
analysis of the pseudorabies virus (PRV) indirect ELISA (ADV (S); 
Idexx Laboratories) results in swine serum and oral fluid samples. 
Serum samples collected ≤7 dpv/dpi were classified as PRV antibody 
negative; samples collected ≥10 dpv/dpi were considered positive. 
Oral samples collected ≤7 dpv/dpi were classified as PRV antibody 
negative; samples collected ≥14 dpv/dpi were considered positive.
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